GlassScriptPhysician profile
Ilan Vavilin
NPI 1578022315
$3,869.75
in general payments reported to CMS, 2019-2025
12 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $485 · 2024: $2,339 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,829 · Travel and Lodging: $815 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.68 |
| Travel and Lodging | $814.98 |
| Education | $226.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,153.66 | 2023-2025 | Gallant, Coroflow, Dragonfly Opstar |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $392.21 | 2023-2025 | Lifevest |
| Abiomed | $277.30 | 2023-2025 | Impella |
| Endotronix, INC. | $222.81 | 2025 | Cordella Pulomonary Artery Pressure Sensor, Cordella Pulmonary Artery Pressure Sensor |
| Asahi Intecc USA, INC. | $158.13 | 2025 | Asahi Coronary Wires |
| Teleflex LLC | $151.18 | 2024 | Guideliner |
| Medtronic, INC. | $124.99 | 2025 | Corevalve Evolut R |
| Shockwave Medical, INC | $116.84 | 2025 | |
| Boston Scientific Corporation | $115.59 | 2023 | Avvigo Guidance System |
| Merck Sharp & Dohme LLC | $102.84 | 2023 | Verquvo |
| Pfizer INC. | $35.00 | 2025 | |
| Amgen INC. | $19.20 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilan Vavilin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.